key: cord-0869555-bo2fhxgr
authors: Bansal, Agam; Kumar, Ashish; Patel, Divyang; Puri, Rishi; Kalra, Ankur; Kapadia, Samir R; Reed, Grant W.
title: Meta-analysis Comparing Outcomes in Patients With and Without Cardiac Injury and Coronavirus Disease 2019 (COVID 19)
date: 2020-11-18
journal: Am J Cardiol
DOI: 10.1016/j.amjcard.2020.11.009
sha: 008de3c7497993786b98389a32bf747d95c7cde7
doc_id: 869555
cord_uid: bo2fhxgr

Current evidence is limited to small studies describing the association between cardiac injury and outcomes in patients with COVID-19. To address this, we performed a comprehensive meta-analysis of studies in COVID-19 patients to evaluate the association between cardiac injury and all-cause mortality, intensive care unit (ICU) admission, mechanical ventilation, acute respiratory distress syndrome (ARDS), acute kidney injury (AKI) and coagulopathy. Further, studies comparing cardiac biomarker levels in survivors versus non-survivors were included. A total of 14 studies (3175 patients) were utilized for the final analysis. Cardiac injury in patients with COVID-19 was associated with higher risk of mortality [RR:7.79; 95%CI: 4.69-13.01; I(2)=58%], ICU admission [RR: 4.06; 95%CI: 1.50-10.97; I(2)=61%], mechanical ventilation [RR: 5.53; 95%CI: 3.09-9.91; I(2)=0%], and developing coagulopathy [RR: 3.86; 95%CI:2.81-5.32; I(2)=0%]. However, cardiac injury was not associated with increased risk of ARDS [RR:3.22; 95%CI:0.72-14.47; I(2)=73%] or AKI [RR: 11.52, 95%CI:0.03-4159.80; I(2)=0%]. The levels of hs-cTnI [MD:34.54 pg/ml;95%CI: 24.67- 44.40 pg/ml; I(2)=88%], myoglobin [MD:186.81 ng/ml;95% CI: 121.52-252.10 ng/ml; I(2)=88%], NT-pro BNP [MD:1183.55 pg/ml; 95% CI: 520.19-1846.91 pg/ml: I(2)=96%] and CK-MB [MD:2.49 ng/ml;95% CI: 1.86-3.12 ng/ml; I(2)=90%] were significantly elevated in non-survivors compared with survivors with COVID-19 infection. The results of this meta-analysis suggest that cardiac injury is associated with higher mortality, ICU admission, mechanical ventilation and coagulopathy in patients with COVID-19.

The 2019 novel coronavirus (2019-nCoV)/severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or COVID-19, was declared as a global pandemic on March 11 th , 2020 1 . As of June 17 th , 2020, COVID-19 has infected more than 8 million individuals with over 416,000 fatalities worldwide 2 . It has been reported that in up to 5% of infected patients, the disease may progress to a critical form manifesting as hypoxic respiratory failure, multiorgan dysfunction or shock, and approximately 2.5% of infected individuals have died from the infection 3 . Acute cardiac injury in patients infected with COVID-19 has been associated with increased risk of all-cause mortality, intensive care unit (ICU) admission, and developing severe COVID-19 infection [4] [5] [6] . However, most studies of outcomes in patients with cardiac injury and COVID-19 have been small, and limited in scope. Further delineation of outcomes with cardiac injury via pooled analysis may be important, as laboratory predictors of clinical deterioration can help stratify risk and assist in appropriate triaging and resource utilization. We therefore systematically reviewed the current scientific literature to perform a meta-analysis determining the association between acute cardiac injury and mortality, ICU admission, ARDS, mechanical ventilation, AKI and coagulopathy in patients with COVID-19.

We carried out an electronic systematic search in Medline (PubMed), Embase, Google Scholar, Cochrane database and medRxiv databases using the keywords "Coronavirus 2019" OR "COVID 19" OR "SARS-CoV-2" OR "severe acute respiratory syndrome coronavirus 2" OR "2019-nCoV" AND "acute cardiac injury" OR "cardiovascular disease" OR "cardiac biomarkers" OR "troponin" or "high-sensitivity cardiac troponins" or "hs-cTnI" or "creatine kinase" or "CK-MB" OR "BNP" OR "NT-pro BNP" OR "myoglobin" between 2019 and June 17, 2020.

The study was performed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA) guidelines [ Figure 1 ]. After removing duplicates, the title and abstracts were independently screened by two authors (AB and RPP). We included the studies reporting cardiac injury associated outcomes defined as either all-cause mortality, ICU admission, ARDS, mechanical ventilation, AKI or coagulopathy, studies with information on cardiac biomarkers (hs-cTnI, myoglobin, CK-MB, NT-pro BNP) in survivors compared with non-survivors of COVID-19 infection. Articles other than original research (i.e. review articles, case reports, letter to editor, editorial or commentaries), duplicate publications and non-English publications were excluded from the analysis. Full texts of the included studies were then reviewed independently by two authors (AB and AK) and data were extracted. Any discrepancies were resolved by the consensus of the authors. To ensure that no potentially important studies were missed, the reference lists from the retrieved articles were also checked.

The following data were collected from each study: author name, year published, country where the study was performed, study design, age, definition of cardiac injury, mean/median cardiac biomarker levels in survivors versus non survivors, following event rates in COVID-19 patients with cardiac injury compared with patients without cardiac injury, all-cause mortality, ICU admission, ARDS, mechanical ventilation, AKI and coagulopathy. The definition of cardiac injury was as per individual studies included. In the studies included, ARDS was defined according to the Berlin definition and AKI was defined according to the Kidney disease: Improving Global Outcomes definition 7, 8 .

Hartung-Knapp-Sidik-Jonkmanthe adjustment to calculate risk ratio (RR) with 95% confidence interval (CI), and inverse variance method with DerSimonian-Laird (DL) method to calculate mean difference (MD) with 95% confidence interval (CI). When the study didn't report mean and the standard deviation, the same were extrapolated from the sample size, median and interquartile range (Q1-Q3) as per Hozo et al. 9 . I 2 statistic was used to assess the heterogeneity between studies. Funnel plot was used to assess publication bias. All statistical analysis was carried out using R version 3.6.3.

Our systematic electronic search retrieved 39 publications after the initial screening of titles and abstracts. Subsequently, 25 studies were excluded, yielding 14 studies 4,10-22 that met the inclusion criteria for studies comparing outcomes in COVID-19 patients with cardiac injury or studies comparing levels of cardiac biomarkers in survivors and non-survivors In total, 8 studies 4, [11] [12] [13] [14] [15] [16] 20 were included for the association of cardiac injury with mortality, 4 studies for ICU admission 3,10,14,22 2 studies for mechanical ventilation 18, 20 , 3 studies for ARDS 14, 18, 20 and 2 studies each for AKI 18, 20 and coagulopathy 18, 20 . With respect to cardiac biomarkers in survivors versus non survivors, 9 studies [11] [12] [13] [15] [16] [17] [18] [19] 21 were included for hs-cTnI and 3 studies each for myoglobin [17] [18] [19] , NT-pro BNP 12, 15, 18 and CK-MB 171821 . Table 1 elucidates the characteristics of the included studies. The present meta-analysis included a total of 3175 patients from 14 studies. A funnel plot assessing publication bias of studies reporting all-cause mortality associated with cardiac injury in COVID patient, indicated that there was no publication bias in our results [ Figure 5 ].

In the present meta-analysis, acute cardiac injury in patients with COVID-19 infection was associated with increased risk of all-cause mortality, ICU admission, need for mechanical ventilation and development of coagulopathy. In addition, the levels of cardiac biomarkers (hs-cTnI, myoglobin, NT-pro BNP and CK-MB) were significantly elevated in COVID 19 non-survivors compared with survivors. Cardiac injury was however not associated with an increased risk of ARDS or AKI.

There are several plausible mechanisms for myocardial injury in COVID-19 patients. This meta-analysis has certain limitations. All of the studies were retrospective in design, were from a single country (China), and few studies were from preprint servers. Also, there was a significant heterogeneity in the reported results likely due to the varied definitions of cardiac injury among the included studies. As such, we were unable to determine whether there is a threshold value for individual cardiac biomarker levels which could be used to predict outcomes.

In conclusion, the results of this meta-analysis suggest that cardiac biomarkers hs- 

Coronavirus Disease (COVID-19) Situation Reports

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China

Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: A meta-analysis

Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis

Acute Respiratory Distress Syndrome: The Berlin Definition

Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)

Estimating the mean and variance from the median, range, and the size of a sample

Clinical features of patients infected with

Clinical features of critically ill patients with COVID-19 infection in China

Radiographic Findings and other Predictors in Adults with Covid-19

Characteristics of patients with COVID-19 during epidemic ongoing outbreak in Wuhan

Heart injury signs are associated with higher and earlier mortality in coronavirus disease

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19

Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease

Myocardial injury is associated with in-hospital mortality of confirmed or suspected COVID-19 in Wuhan, China: A single center retrospective cohort study

Clinical Features of Patients Infected with the 2019 Novel Coronavirus (COVID-19

Angiotensin Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System

Myocardial injury and COVID-19: Possible mechanisms

Severe Acute Respiratory Syndrome-associated Coronavirus Nucleocapsid Protein Interacts with Smad3 and Modulates Transforming Growth Factor-β Signaling